Lénaïg Tanneau

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Lénaïg Tanneau, Elin M. Svensson, Stefaan Rossenu et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 34 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis

Lénaïg Tanneau, Mats O. Karlsson, Elin M. Svensson · British Journal of Clinical Pharmacology · 2019 · 21 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Lénaïg Tanneau, Mats O. Karlsson, Susan L. Rosenkranz et al. · Clinical Pharmacology & Therapeutics · 2022 · 20 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

Lénaïg Tanneau, Mats O. Karlsson, Andreas H. Diacon et al. · Clinical Pharmacokinetics · 2022 · 15 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment

Stijn W. van Beek, Lénaïg Tanneau, Graeme Meintjes et al. · Open Forum Infectious Diseases · 2022 · 10 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17